TNFRSF8 and anaplastic large cell lymphoma: In 2018, the FDA also approved brentuximab vedotin for the treatment of untreated systemic anaplastic large-cell lymphoma (ALCL) or other CD30+ T-cell lymphomas (TCLs) with cyclophosphamide, doxorubicin, and prednisone (CHP).